Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related news

Vinge advises Ramirent in connection with its acquisition of JIAB

Vinge advises Ramirent AB in connection with its acquisition of JIAB Hyrcenter (consisting of the companies JIAB Hyrcenter AB and JIAB Boden AB). Ramirent thereby further strengthens its position in Norrbotten and as the largest machine rental company in Sweden.
March 21, 2023

Vinge has advised Svea Bank AB in connection with the issuance of Additional Tier 1 Capital of SEK 300 million

Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of additional tier 1 capital (AT1) of SEK 300 million to optimise its capital structure.
March 14, 2023

Vinge advises Anglo American in connection with investment in the Dannemora mine

Vinge has, together with Norton Rose Fulbright, advised Anglo American Limited in connection with entering into a royalty agreement of USD 10 million and a binding term sheet for an offtake agreement with Dannemora Iron AB. Moreover, Vinge has assisted with thereto related due diligence. Dannemora Iron AB is a wholly owned subsidiary of Grängesberg Exploration Holding AB (publ).
March 14, 2023